News & Updates

Local failure common in metastases from right-sided primary CRC treated with SABR
Local failure common in metastases from right-sided primary CRC treated with SABR
31 Oct 2021

Local failure (LF) is more likely to occur in colorectal cancer (CRC) metastases treated with stereotactic ablative radiotherapy (SABR) if originating from right-sided primary CRC compared with left-sided, a study has found. In addition, LF rates are highest with liver metastases than other metastatic sites.

Local failure common in metastases from right-sided primary CRC treated with SABR
31 Oct 2021
Patients presenting with advanced-stage pancreatic cancer reveal cracks in imaging-based surveillance
Patients presenting with advanced-stage pancreatic cancer reveal cracks in imaging-based surveillance
31 Oct 2021

High-risk individuals who develop neoplastic progression to pancreatic cancer or high-grade dysplasia can present at an advanced stage despite showing no lesions during prior imaging surveillance evaluations, a new study has found.

Patients presenting with advanced-stage pancreatic cancer reveal cracks in imaging-based surveillance
31 Oct 2021
Dietary ALA intake may lower risks of all-cause, CVD, CHD mortality
Dietary ALA intake may lower risks of all-cause, CVD, CHD mortality
28 Oct 2021 byStephen Padilla

Dietary intake of alpha linolenic acid (ALA) appears to reduce the risk of mortality from all causes, cardiovascular disease (CVD), and coronary heart disease (CHD) but may slightly increase the risk of cancer mortality, according to a systematic review and meta-analysis. Moreover, an association exists between higher blood levels of ALA and a lower risk of all-cause and CHD mortality.

Dietary ALA intake may lower risks of all-cause, CVD, CHD mortality
28 Oct 2021
Adjuvant atezolizumab improves DFS in early-stage NSCLC
Adjuvant atezolizumab improves DFS in early-stage NSCLC
27 Oct 2021 byRoshini Claire Anthony

In patients with completely resected stage II–IIIA non-small-cell lung cancer (NSCLC) who had previously received adjuvant cisplatin chemotherapy, adjuvant atezolizumab extended disease-free survival (DFS), particularly in those with PD-L1 expression 1 percent on tumour cells, interim results of the phase III IMpower010 trial showed.

Adjuvant atezolizumab improves DFS in early-stage NSCLC
27 Oct 2021
Chronic constipation not a risk factor for later colorectal cancer
Chronic constipation not a risk factor for later colorectal cancer
27 Oct 2021

Individuals with chronic constipation do not seem to be at increased risk of developing subsequent colorectal cancer as compared with their peers who do not have the gastrointestinal condition, as reported in a study.

Chronic constipation not a risk factor for later colorectal cancer
27 Oct 2021